HBO1-MLL interaction inhibitors would complement the therapeutic effects of the emerging MENIN-MLL interaction inhibitors (Klossowski et al., 2019; Krivtsov et al., 2019) to treat malignant leukemia with subsets of MLL and NUP98 fusions. This evidence concerns the gene MEN1 and leukemia.